HMGB2 and ovarian carcinoma: In addition, HMGB2 has been proved to be an independent influencing factor of the patient’s prognosis by its protein or mRNA level in hepatocellular carcinoma, epithelial ovarian cancer and glioblastoma multiforme (Ouellet et al., 2006; Kwon et al., 2010; Wu et al., 2013).